“The PtCr alloy and stent architecture used in the Element platform offer significant advantages in conformability and radiopacity compared to other stent platforms,” said Colombo. “I believe the improved deliverability of the Promus Element Plus stent system will add another significant benefit, especially when accessing challenging lesions. This innovative stent is also supported by strong clinical outcomes from the PLATINUM trials, which demonstrated very low rates of revascularisation and stent thrombosis at one year.”
The Promus Element Plus stent system employs an advanced low-profile delivery system featuring a dual-layer balloon designed to enable precise stent delivery across challenging lesions and reduce balloon growth during inflation to facilitate high-pressure stent deployment. The everolimus drug and fluorinated copolymer used on the Promus Element stent have been studied in multiple randomised clinical trials and ‘real-world’ registries, demonstrating excellent long-term safety and efficacy.
The Promus Element stent system received CE mark approval in 2009 and the Promus Element Plus stent system in 2011. In the USA, the Promus Element Plus was approved by the Food and Drug Administration (FDA) in November 2011.
